8-K: Dentsply Sirona Q3 Sales Decline, Launches Growth Plan

Dentsply Sirona reported a 5.0% net sales decrease in Q3 2025, announced a new 'Return-to-Growth' action plan, and revised its full-year outlook downwards.

Summary

• Net sales for Q3 2025 were $904 million, a 5.0% decrease as-reported and an 8.0% decrease in constant currency compared to Q3 2024.
• GAAP net loss per share was ($2.14), an improvement from ($2.46) in Q3 2024.
• Adjusted EPS decreased by 26.5% to $0.37 from $0.50 in Q3 2024.
• The company recorded a non-cash impairment charge of ($263) million for goodwill and intangible assets, primarily due to lower volumes in the U.S. and tariff impacts.
• A 'Return-to-Growth' action plan has been introduced, focusing on customer experience, U.S. business revitalization, empowering employees, and operational evolution.
• Leadership changes include the departure of CFO Matt Garth, the appointment of Aldo Denti as Chief Commercial Officer, and Dustin Shields as Chief Transformation Officer.
• The full-year 2025 outlook has been revised, with net sales expected between $3.6 billion and $3.7 billion, and adjusted EPS around $1.60.

Sentiment

Score: 3

Explanation: The company reported significant sales declines and a substantial drop in adjusted EPS, leading to a downward revision of its full-year outlook. While management is taking decisive action with a new 'Return-to-Growth' plan and leadership changes, the immediate financial performance is poor, and the impairment charge highlights underlying operational challenges, particularly in the crucial U.S. market. The slight improvement in GAAP net loss and adjusted EBITDA margin are minor positives against a backdrop of overall underperformance.

Positives

• GAAP net loss per share improved to ($2.14) from ($2.46) in the prior year.
• Adjusted EBITDA margin slightly increased to 18.4% from 17.9% in Q3 2024.
• Cash and cash equivalents increased to $363 million as of September 30, 2025, from $272 million at December 31, 2024.
• Wellspect Healthcare segment showed strong growth, with net sales increasing 15.6% as-reported and 9.3% in constant currency.
• Europe region net sales increased 9.9% as-reported and 2.6% in constant currency.
• Lower non-cash impairment charges for goodwill and intangible assets compared to the prior year ($263 million vs. $495 million).
• Proactive launch of a 'Return-to-Growth' action plan and strategic leadership appointments to address challenges.

Negatives

• Net sales decreased 5.0% as-reported and 8.0% in constant currency to $904 million.
• Adjusted EPS decreased significantly by 26.5% to $0.37.
• Operating cash flow decreased to $79 million from $141 million in Q3 2024, primarily due to unfavorable working capital changes.
• Significant decline in U.S. net sales, down 22.2% in constant currency.
• Connected Technology Solutions, Essential Dental Solutions, and Orthodontic and Implant Solutions segments all experienced constant currency sales declines of 7.0%, 6.2%, and 17.1% respectively.
• Full-year 2025 outlook for net sales and adjusted EPS has been revised downwards.
• The company recorded a substantial non-cash impairment charge of ($263) million.

Risks

• Lower-than-expected volumes of equipment, implants, and prosthetics products, particularly in the United States.
• Impacts from tariffs.
• General risks and uncertainties that could cause actual results to differ materially from forward-looking statements, as detailed in the Company's Form 10-K and 10-Q filings.
• Operational and strategic challenges facing the business.

Future Outlook

The company has revised its full-year 2025 outlook, now expecting net sales in the range of $3.6 billion to $3.7 billion, with constant currency sales decreasing between 5% and 4% year-over-year. Adjusted EPS is projected to be approximately $1.60. This outlook incorporates current tariffs and trade policy, and anticipates incremental investments in the fourth quarter.

Management Comments

• "Third quarter results fell short of our expectations and reflect the operational and strategic challenges facing the business."
• "The Board of Directors and I are taking decisive action to improve performance with the launch of our Return-to-Growth strategy."
• "By sharpening our focus on our customers, reigniting growth in the U.S. business, more effectively empowering our people to power performance and evolving our operations to drive innovation, we believe we will be able to deliver sustained, profitable growth over the next 24 months and enhance long-term value for Dentsply Sirona shareholders."

Industry Context

The dental products and technologies industry, particularly in the U.S., appears to be facing headwinds, as evidenced by Dentsply Sirona's significant sales decline in the region and lower-than-expected volumes for equipment, implants, and prosthetics. The company's focus on digital, AI, and transformation initiatives aligns with broader trends in healthcare technology, suggesting an effort to modernize and gain competitive advantage in a challenging market. The appointment of a Chief Commercial Officer with extensive medical device experience and a Chief Transformation Officer indicates a strategic pivot towards aggressive market penetration and operational efficiency, which could set a new benchmark for competitors if successful.

Comparison to Industry Standards

• The significant 22.2% constant currency sales decline in the United States for Dentsply Sirona's dental products and technologies suggests underperformance relative to a potentially more stable or growing market, though no specific comparable companies or projects are mentioned in the filing.
• The 9.3% constant currency growth in the Wellspect Healthcare segment, which focuses on consumable medical devices, indicates a strong performance in that specific niche, potentially outperforming general medical device market growth rates.
• The overall 8.0% constant currency sales decline and 26.5% adjusted EPS drop suggest Dentsply Sirona is currently lagging behind industry leaders or average growth rates in the broader dental and medical device sectors, which often aim for single-digit to low double-digit revenue growth.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Negative impact due to significant sales decline, reduced adjusted EPS, downward revised outlook, and a substantial goodwill impairment charge. The 'Return-to-Growth' plan aims to enhance long-term value, but immediate returns are challenged.
• Employees: Potential impact from restructuring initiatives (mentioned as a non-GAAP adjustment category) and the focus on 'empowering people to power performance' suggests internal changes and a push for accountability. Leadership changes at the executive level indicate a shift in strategic direction.
• Customers: The 'Putting Customers at the Center' pillar aims to enhance customer experience by simplifying processes, empowering field teams, and strengthening global service capabilities, suggesting a positive future impact if successful.
• Creditors: Operating cash flow decreased, but cash and cash equivalents increased, and the company paid dividends. The long-term debt increased from $1,586 million (Dec 31, 2024) to $2,017 million (Sept 30, 2025), which could be a concern if performance doesn't improve.

Next Steps

• Execution of the 'Return-to-Growth' action plan over the next 24 months.
• Search for a successor to the departed Chief Financial Officer.
• Dan Scavilla, President and CEO, will provide further details on the action plan during the Q3 2025 earnings call webcast.
• Dustin Shields will oversee the day-to-day execution of the Return-to-Growth plan, including AI and automation initiatives, starting December 1, 2025.
• Incremental investments are expected to occur in the fourth quarter of 2025.

Key Dates

Recommendation

Dentsply Sirona's Q3 2025 results were significantly weaker than expected, marked by substantial sales declines, a sharp drop in adjusted EPS, and a downward revision of the full-year outlook. The goodwill impairment charge further underscores underlying operational challenges, particularly in the critical U.S. market. While the new 'Return-to-Growth' action plan and strategic leadership appointments demonstrate management's commitment to addressing these issues, the plan's success is uncertain and will take 24 months to materialize. Given the current underperformance and the long-term nature of the turnaround strategy, a 'hold' recommendation is appropriate. Investors should monitor the execution of the growth plan and subsequent quarterly results for signs of improvement before considering further investment, while existing investors should hold to see if the strategic initiatives can reverse the negative trends.

Keywords

Dentsply Sirona, XRAY, Q3 2025 Earnings, Dental Products, Medical Devices, Financial Results, Sales Decline, Adjusted EPS, Goodwill Impairment, Return-to-Growth Plan, Leadership Changes, CFO Departure, Chief Commercial Officer, Chief Transformation Officer, FY25 Outlook, Dental Technology, Orthodontics, Implants, Healthcare